XORTX Therapeutics (XRTX) news
Recent news
Xortx Therapeutics shares rise 23% above $2 after the bell following update on Health Canada clinical trial application of treatment for gout
XORTX Therapeutics Inc. (XRTX) saw its shares rise 23% above $2 in after-hours trading following an update on its clinical trial application for a gout treatment. The company announced progress in its regulatory submissions, including plans to submit an Investigational New Drug (IND) application to…
AInvest Wire · 6d agoXortx Therapeutics - Application outlines plan to advance XRX-026 toward regulatory approval in Canada and NDA filing with FDA
AInvest Wire · 6d agoXortx Therapeutics - First part of XRX-OXY-102 study in Canada expected to accelerate NDA filing with FDA
AInvest Wire · 6d agoXortx Therapeutics - Receives increased inquiries from potential commercialization partners for XRX-026
XORTX Therapeutics Inc. (NASDAQ: XRTX) has reported a notable increase in inquiries from potential commercialization partners regarding its XRX-026 program. This development follows recent progress in the company’s research and development pipeline, which has drawn interest from industry…
AInvest Wire · 6d agoXortx outlines anticipated Health Canada clinical trial application for XRX-026 for gout
AInvest Wire · 6d agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.